Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Gogoro Inc (GGR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Gogoro Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Gogoro Inc trades at $3.85 (market cap $77.28M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 516.2× Gogoro Inc's market cap, and Gogoro Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | GGR | |
|---|---|---|
Market Cap | $39.89B | $77.28M |
Sector | Health | Technology |
52-Week High | $491.22 | $7.89 |
52-Week Low | $278.09 | $2.74 |
Enterprise Value | $38.15B | $379.73M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
GGR trades at $3.85, up 1.72% today, but faces significant fundamental challenges with a net loss of $79.97 million in 2025 and negative profit margins. Technical indicators show a bearish trend with mixed signals from oscillators. The company's cash flow remains negative despite operational improvements, while analyst consensus remains neutral with 100% hold ratings.
The outlook remains cautious as GGR struggles with profitability despite revenue stability. Investment opportunity exists in the company's low valuation multiples and battery-swapping technology growth, but risks include persistent losses, negative cash flow, and execution challenges in competitive sustainable mobility markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Gogoro Inc
Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →
